Tenet Healthcare (THC) – Investment Analysts’ Weekly Ratings Changes

Tenet Healthcare (NYSE: THC) recently received a number of ratings updates from brokerages and research firms:

• 11/4/2026 – Tenet Healthcare had its price target raised by Barclays from $271.00 to $297.00. They now have an “overweight” rating on the stock.
• 11/3/2026 – Tenet Healthcare had its “buy” rating reaffirmed by Truist Financial. They now have a $305.00 price target on the stock, up from $290.00.
• 11/3/2026 – Tenet Healthcare had its price target raised by KeyCorp from $270.00 to $300.00. They now have an “overweight” rating on the stock.
• 11/2/2026 – Tenet Healthcare was given a new $305.00 price target by Mizuho.
• 11/2/2026 – Tenet Healthcare had its price target raised by Leerink Partners from $309.00 to $342.00. They now have an “outperform” rating on the stock.
• 11/2/2026 – Tenet Healthcare had its price target raised by Royal Bank Of Canada from $283.00 to $304.00. They now have an “outperform” rating on the stock.
• 11/2/2026 – Tenet Healthcare had its price target raised by Wells Fargo & Company from $281.00 to $321.00. They now have an “overweight” rating on the stock.
• 10/30/2026 – Tenet Healthcare had its price target raised by Deutsche Bank Aktiengesellschaft from $260.00 to $320.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Tenet Healthcare had its price target lowered by Guggenheim from $307.00 to $306.00. They now have a “buy” rating on the stock.
• 10/17/2026 – Tenet Healthcare was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 10/16/2026 – Tenet Healthcare had its price target raised by Guggenheim from $283.00 to $307.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Tenet Healthcare was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 10/3/2026 – Tenet Healthcare was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/2/2026 – Tenet Healthcare had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/29/2026 – Tenet Healthcare was downgraded by Zacks Research from “strong-buy” to “hold”.
• 9/22/2026 – Tenet Healthcare is now covered by BMO Capital Markets. They set a “market perform” rating and a $265.00 price target on the stock.
• 9/22/2026 – Tenet Healthcare is now covered by BMO Capital Markets. They set a “market perform” rating and a $265.00 price target on the stock.
• 9/18/2026 – Tenet Healthcare had its “outperform” rating reaffirmed by Leerink Partners. They now have a $309.00 price target on the stock.

Tenet Healthcare Trading Down 0.9%

THC traded down $2.66 on Friday, reaching $283.80. 289,362 shares of the company’s stock were exchanged, compared to its average volume of 1,121,100. Tenet Healthcare Corporation has a twelve month low of $157.58 and a twelve month high of $301.44. The company’s 50 day moving average is $265.00 and its 200-day moving average is $221.94. The company has a debt-to-equity ratio of 1.76, a quick ratio of 1.52 and a current ratio of 1.58. The company has a market cap of $22.59 billion, a price-to-earnings ratio of 8.23, a PEG ratio of 1.56 and a beta of 1.20.

Tenet Healthcare (NYSE:THC) last released its quarterly earnings data on Thursday, October 29th. The company reported $6.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.68 by $1.96. Tenet Healthcare had a net margin of 13.09% and a return on equity of 28.22%. The company had revenue of $6.28 billion during the quarter, compared to the consensus estimate of $5.49 billion. During the same period in the previous year, the firm earned $3.70 earnings per share. Tenet Healthcare’s revenue for the quarter was up 6.5% on a year-over-year basis. Equities analysts predict that Tenet Healthcare Corporation will post 22.32 earnings per share for the current year.

Insider Buying and Selling

In other Tenet Healthcare news, EVP Lisa Y. Foo sold 24,000 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $266.32, for a total value of $6,391,680.00. Following the completion of the transaction, the executive vice president owned 8,053 shares in the company, valued at $2,144,674.96. This represents a 74.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director J. Robert Kerrey sold 12,010 shares of Tenet Healthcare stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $263.72, for a total transaction of $3,167,277.20. Following the sale, the director owned 4,794 shares in the company, valued at $1,264,273.68. This represents a 71.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 98,462 shares of company stock valued at $26,788,234 over the last ninety days. Insiders own 0.97% of the company’s stock.

Tenet Healthcare Corp. (NYSE: THC) is a diversified healthcare services company headquartered in Dallas, Texas. Through its hospital operations and outpatient platforms, the company provides a range of medical services to patients across the United States.

Tenet operates acute care and specialty hospitals, ambulatory surgery centers, imaging facilities and other outpatient care sites. Its United Surgical Partners International subsidiary is a major provider of ambulatory surgery services and partners with physicians and health systems.